Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,268,540 papers from all fields of science
Search
Sign In
Create Free Account
Antibodies, Monoclonal, Humanized
Known as:
Humanized Monoclonal Antibody
, Antibodies, Monoclonal, Humanized [Chemical/Ingredient]
, Antibodies, Humanized
Expand
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
50 relations
Narrower (48)
89Zr-bevacizumab
AVE1642
BIIB036
BIW-8962
Expand
In Blood
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program
M. Bigal
,
R. Escandon
,
+4 authors
P. Garzone
Cephalalgia
2014
Corpus ID: 46350349
Background LBR-101 is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide. Objective The…
Expand
Highly Cited
2013
Highly Cited
2013
Monoclonal antibody humanness score and its applications
Sean H Gao
,
Kexin Huang
,
H. Tu
,
A. Adler
BMC Biotechnology
2013
Corpus ID: 2268897
BackgroundMonoclonal antibody therapeutics are rapidly gaining in popularity for the treatment of a myriad of diseases, ranging…
Expand
Review
2011
Review
2011
Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
Deborah A. Smith
,
E. Minthorn
,
M. Beerahee
Clinical Pharmacokinetics
2011
Corpus ID: 161123
Mepolizumab is a fully humanized monoclonal antibody (IgG1/κ) targeting human interleukin-5 (IL-5), a key haematopoietin needed…
Expand
Review
2009
Review
2009
Antibody-conjugated nanoparticles for biomedical applications
M. Arruebo
,
M. Valladares
,
Á. González-Fernández
2009
Corpus ID: 55422494
Nanoscience and Nanotechnology have found their way into the fields of Biotechnology and Medicine. Nanoparticles by themselves…
Expand
Highly Cited
2009
Highly Cited
2009
Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
T. Miller
,
J. T. Forbes
,
+11 authors
C. Arteaga
Clinical Cancer Research
2009
Corpus ID: 11579699
Purpose: A significant fraction of HER2-overexpressing breast cancers exhibit resistance to the HER2 antibody trastuzumab…
Expand
Highly Cited
2007
Highly Cited
2007
Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus.
Ziping Wei
,
Jinhua Feng
,
+7 authors
M. Schenerman
Analytical Chemistry
2007
Corpus ID: 25542706
We have identified a single tryptophan (Trp) residue responsible for loss of binding and biological activity upon ultraviolet (UV…
Expand
Highly Cited
2005
Highly Cited
2005
Development of humanized antibodies as cancer therapeutics.
Z. Qu
,
G. Griffiths
,
+5 authors
D. Goldenberg
Methods
2005
Corpus ID: 378909
Highly Cited
2002
Highly Cited
2002
Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.
F. Vajdos
,
C. Adams
,
T. Breece
,
L. Presta
,
A. D. de Vos
,
S. Sidhu
Journal of Molecular Biology
2002
Corpus ID: 23109516
Review
2002
Review
2002
Myeloma expression systems.
Esther M. Yoo
,
K. Chintalacharuvu
,
M. Penichet
,
S. Morrison
JIM - Journal of Immunological Methods
2002
Corpus ID: 30796109
1995
1995
Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H.
D. Ashton
,
C. Beddell
,
+4 authors
M. Smith
Analytical Chemistry
1995
Corpus ID: 21982171
Two mass spectrometric techniques, electrospray ionization (ESI) and matrix-assisted laser desorption ionization (MALDI) have…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE